Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Depression (Treatment-Resistant) Clinical Trials

A listing of Depression (Treatment-Resistant) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (9) clinical trials

The purpose of this study is to evaluate a new treatment for people suffering from depression.

Phase

This is a Phase 3b multicenter study of adjunctive ALKS 5461 2/2 that will utilize a randomized, double-blind, 2-stage, placebo-controlled, sequential parallel comparison design (SPCD). The purpose of this study is to evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 2/2 (2 mg buprenorphine [BUP]/2 mg samidorphan [SAM]) ...

Phase

Inadequate response to antidepressant treatment? California Neuroscience Research is conducting a research study to evaluate an investigational medication in persons with treatment resistant Major Depressive Disorder.

Phase

Berlin Deep Brain Stimulation Depression Study

In this study efficacy and safety of deep brain stimulation of the cingulate cortex in 20 patients with treatment resistant major depression will be investigated. In addition, the stress axis, the cortical GABAergic system, neurotrophins and event-related potentials will be assessed.

Phase

A Long-term Safety Study of Intranasal Esketamine in Treatment-resistant Depression

This is an open-label (the researchers and participants know the treatment the participant is receiving) long-term extension study. The study will consist of 2 open-label Phases: 4-week Induction phase (if applicable) and Open-Label Optimization/Maintenance phase (variable). Participants will enter the study Induction Phase from ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585), ESKETINTRD3003 (NCT02493868), ...

Phase

Ketamine for Treatment Resistant Late-Life Depression

Primary Aim: To identify and evaluate the durability of benefit of the best performing of 3 sub-anesthetic doses of a single ketamine (0.1 mg/kg, 0.25 mg/kg, and 0.50 mg/kg) and midazolam (MID) (0.03 mg/kg) infusion in up to 72 Veterans with Late-Life Treatment Resistant Depression (LL-TRD). Hypothesis 1: the durability ...

Phase

A Study to Evaluate the Efficacy Pharmacokinetics Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

The purpose of this study is to evaluate the efficacy of switching adult participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to flexibly dosed intranasal esketamine (56 milligram [mg] or 84 mg) plus a newly initiated oral antidepressant compared with switching to ...

Phase

Evaluation of Schemes of Administration of Intravenous Ketamine in Depression

Background 1.1 Major depressive disorder (MDD) MDD is a clinical syndrome characterized by the presence of low modo, anhedonia, appetite and weight changes, sleep disturbances, psychomotor alterations, fatigue, guilt and low self-esteem, ideas related to death or suicide, and concentration difficulties. MDD represents one of the first causes of disability ...

Phase